Business Context and Reporting Period
This Form 8-K Current Report, dated July 2, 2019, details a material definitive agreement entered into by Medtronic Public Limited Company (Medtronic plc). The filing reports on a debt offering executed by Medtronic Global Holdings S.C.A. ("Medtronic Luxco"), an indirect wholly-owned subsidiary of Medtronic plc, to refinance existing debt obligations.
Key Financial Metrics and Transaction Details
The company issued a total of approximately €6.0 billion in aggregate principal amount of senior notes. The net proceeds from the offering are expected to be approximately €4.9 billion after deducting underwriting discounts and estimated offering expenses.
| Note Series | Principal Amount (€) | Interest Rate | Maturity Date |
|---|---|---|---|
| Floating Rate Senior Notes | 250,000,000 | 3-month EURIBOR + 0.200% (min 0%) | March 7, 2021 |
| 0.00% Senior Notes | 750,000,000 | 0.00% | December 2, 2022 |
| 0.25% Senior Notes | 1,000,000,000 | 0.25% | July 2, 2025 |
| 1.00% Senior Notes | 1,000,000,000 | 1.00% | July 2, 2031 |
| 1.50% Senior Notes | 1,000,000,000 | 1.50% | July 2, 2039 |
| 1.75% Senior Notes | 1,000,000,000 | 1.75% | July 2, 2049 |
The notes are fully and unconditionally guaranteed by Medtronic plc and Medtronic, Inc. They rank equally with other existing unsecured senior indebtedness.
Material Changes and Use of Proceeds
The primary material change is the execution of a new debt offering to fund previously announced tender offers for several series of outstanding notes. The net proceeds will be used to:
- Fund the tender offers for outstanding notes issued by Medtronic, Inc., Medtronic Luxco, and Covidien International Finance S.A.
- Pay accrued and unpaid interest, premiums, fees, and expenses related to the tender offers.
- Repay other indebtedness and fund general corporate purposes with any remaining proceeds.
Guidance, Outlook, and Management Commentary
Management expects the new offering and the associated tender offers to be effectively leverage neutral. The transactions are anticipated to result in lower fiscal year 2020 interest expense, though this will be slightly offset by increased U.S. tax. Management does not anticipate a material impact on Q1 FY20 financial results, as the tender offers are not expected to be completed until late in the quarter. Final financial impacts will be determinable no earlier than July 10, 2019.
Forward-looking statements in the filing are subject to risks regarding the acceptance of tendered notes, the expiration and settlement of tender offers, and general economic conditions.
Key Facts for Investor Verification
- Transaction Size: Verify the final net proceeds of approximately €4.9 billion against the gross issuance of €6.0 billion.
- Refinancing Impact: Confirm the specific outstanding notes being retired via the tender offers to assess the net reduction in interest expense.
- Settlement Timing: Monitor the completion of the tender offers, expected by July 10, 2019, to finalize the financial impact on FY20.
- Guarantee Structure: Note that the notes are guaranteed by Medtronic plc and Medtronic, Inc., but are structurally subordinated to obligations of other subsidiaries.
- Call Provisions: Review the specific "par call dates" for each note series, which allow redemption at 100% of principal plus accrued interest after specific dates.